期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 21, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ijms21062193
关键词
acute lymphoblastic leukemia; CRLF2; PI3K; AKT; mTOR; targeted therapy
资金
- National Cancer Institute of the National Institutes of Health [R01CA209829]
Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk B-cell Acute Lymphoblastic Leukemia (B-ALL) characterized by a gene expression profile similar to Ph-positive B-ALL but lacking the BCR-ABL1 translocation. The molecular pathogenesis of Ph-like B-ALL is heterogenous and involves aberrant genomics, receptor overexpression, kinase fusions, and mutations leading to kinase signaling activation, leukemogenic cellular proliferation, and differentiation blockade. Testing for the Ph-like signature, once only a research technique, is now available to the clinical oncologist. The plethora of data pointing to poor outcomes for this ALL subset has triggered investigations into the role of targeted therapies, predominantly involving tyrosine kinase inhibitors that are showing promising results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据